Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... from Takamatsu, Japan, "Recent studies indicate a role of chymase in the regulation of angiotensinII (AngII) formation in cardiovascular and renal tissues. We investigated a possible ... acid (50 mg/kg, twice a day, p.o.), or the selective AT(1)-receptorblocker olmesartan (10 mg/kg per day, p.o.) for 14 days. UUO-induced renal interstitial ...
2009 OCT 19 ... combination products. Fixed-dose combinations containing chlorthalidone and an angiotensin-receptorblocker are now in development," wrote D.A. Sica and colleagues, Virginia ... London EC2A 4LQ, England. Keywords: United States, Richmond, Angiotensin II Receptor Antagonist, Antiarrhythmic, Antihypertensive, Chlorthalidone, Drugs, ...
2009 NOV 2 ... Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis=AE (telmisartan) Tablets 80 mg for reduction of the risk of myocardial ...
2009 NOV 9 ... Kawamura and colleagues published their study in Reproductive Sciences (Angiotensin II Receptor Blocker Candesartan Cilexetil, but Not Hydralazine Hydrochloride, Protects Against Mouse Cardiac ...
2009 NOV 9 ... the effects between calcium channel blockers and diuretics when used in combination with angiotensin II receptor blocker on aortic systolic blood pressure (BP) and brachial ambulatory systolic BP. We conducted ...
2009 OCT 19 ... (24-h mean baseline ambulatory BP similar to 148/93 mm Hg) randomized to the angiotensinreceptorblocker, telmisartan (80 mg; n = 802), or the angiotensin-converting enzyme ... efficacy of Micardis vs Ramipril Using ABPM (ambulatory BP monitoring) (PRISMA) I and II, BP control was compared in patients with essential hypertension (24-h mean baseline ...
2009 NOV 9 ... is deposition of amyloid-beta protein (A beta) in the brain. Telmisartan is a unique angiotensin II receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma) stimulating ...
2009 NOV 23 ... was lower in the women, on average. The lower ACEI dose may reflect the higher use of angiotensin II receptor blocker (ARB) in women. Both the peak VO2 and the 6-minute walk distance were significantly ...
2009 NOV 1 ... According to a study from Edmonton, Canada, "Angiotensin- converting enzyme 2 (ACE2) is a monocarboxypeptidase that metabolizes Ang II into Ang ... and JNK1/2 signaling pathways. Treatment of Ace2(-/y)-MI mice with irbesartan, an AT1 receptorblocker, reduced nicotinamide-adenine dinucleotide phosphate oxidase activity, infarct ...
2009 OCT 19 ... Data detailed in 'Effects of angiotensinreceptor blockade on serial P-wave signal-averaged electrocardiograms after electrical ... in Oslo, Norway conducted a study "To evaluate the effects of the angiotensin II type 1 receptor blocker candesartan on P-wave signal-averaged electrocardiogram ...
2009 NOV 23 ... "Several studies have implicated the renin angiotensin system in the cardiac hypertrophy induced by thyroid hormone. However, whether ... the activation of this signaling pathway. We also reported that local Angiotensin I/II (Ang I/II) levels (120%, P< 0.05) and the AT(1)R expression (180%, P< 0.05) were ... the cardiac hypertrophy induced by thyroid hormone. However, whether Angiotensin type 1 receptor (AT(1)R) is critically required to the development of T-3-induced cardiomyocyte ... questions, we employed a selective small interfering RNA (siRNA, 50 nM) or an AT(1)R blocker (Losartan, 1 mc M) to evaluate the specific role of this receptor in primary cultures of ...
2009 OCT 12 ... transplanted into Lewis rats. Eight recipient rats were treated with placebo or an angiotensinII type-1 receptorblocker (AT1RB; candesartan cilexitil, 5 mg/kg/d) for 24 weeks ...
2009 NOV 23 ... According to recent research from the United States, "The renin-angiotensin-aldosterone system (RAAS), an important regulator of blood pressure as well as fluid and ... of the RAAS with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II (ANG-II) receptor blockers (ARBs) lowers blood pressure, decreases morbidity and ... System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. American Journal of Hypertension, 2009;22(10):1032-1040). For ...
2009 OCT 12 ... drugs with anti-inflammatory effects might effectively treat CA formation. As renin angiotensin system (RAS) is a major inflammatory cascade and related to various vascular diseases, ... to various vascular diseases, including aortic aneurysms, the role of angiotensin (Ang) II type 1 receptor might contribute to the progression of CAs. However, in cerebral ... was not up-regulated. In addition, subcutaneously administered Ang II type 1 receptor blocker did not inhibit CA formation, nor inflammation in cerebral aneurysmal walls in rat ...
2009 NOV 9 ... (MMP)-9 secretion by these cells." "We investigated the effects of the angiotensinII type 1 receptor antagonist losartan and its metabolites (EXP3174 and EXP3179) on ... hypertensives compared with the other group of patients. Thus, EXP3179 acts as a blocker of the NADPH oxidase in phagocytic cells by a potential mechanism that targets the ...
